A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Date publication

juin 2018

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Dr HABERSETZER François , Dr MINELLO Anne

Tous les auteurs :
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29874528

Résumé

Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome proliferator-activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with this condition.

Mots clés

Adult, Bezafibrate, adverse effects, Bile Acids and Salts, blood, Cholangitis, drug therapy, Double-Blind Method, Female, Humans, Hypolipidemic Agents, adverse effects, Liver Cirrhosis, Biliary, complications, Male, Middle Aged, Placebos, therapeutic use, Treatment Failure, Ursodeoxycholic Acid, therapeutic use

Référence

N. Engl. J. Med.. 2018 06 7;378(23):2171-2181